Pacific Shuanglin Bio-pharmacy Co., LTD (SHE:000403)
China · Delayed Price · Currency is CNY 18.42
+0.42 (2.33%)
Sep 8, 2025, 2:45 PM CST
SHE:000403 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Jan '21 Jan 1, 2021 | 2016 - 2020 |
Net Income | 654.13 | 745.32 | 612.11 | 587.13 | 391.06 | 185.97 | Upgrade |
Depreciation & Amortization | 125.34 | 127.14 | 145.47 | 126.39 | 115.76 | 47.37 | Upgrade |
Other Amortization | 13.28 | 8.75 | 0.65 | 4.43 | 7.39 | 8.36 | Upgrade |
Loss (Gain) From Sale of Assets | 0.02 | 0.12 | 0.54 | -0.44 | -0.27 | -0.02 | Upgrade |
Asset Writedown & Restructuring Costs | 3.77 | 3.46 | 1.29 | 3.59 | 103.67 | 5.27 | Upgrade |
Loss (Gain) From Sale of Investments | -20.94 | -24.12 | -17.56 | -7.97 | -77.91 | - | Upgrade |
Provision & Write-off of Bad Debts | -4.01 | -4.6 | -2.04 | 9.66 | 9.44 | -3.69 | Upgrade |
Other Operating Activities | -35.97 | -39.45 | -14.95 | -38.62 | -33.92 | -1.24 | Upgrade |
Change in Accounts Receivable | -120.65 | -131.42 | 274.65 | -329.07 | -196.58 | -89.04 | Upgrade |
Change in Inventory | -462.96 | -325.13 | -285.42 | 115.51 | 1.72 | -37.11 | Upgrade |
Change in Accounts Payable | -138.13 | -47.76 | -31.26 | 70.94 | 70.06 | 57.62 | Upgrade |
Change in Other Net Operating Assets | - | - | 2.23 | 10.6 | 21.65 | 22.44 | Upgrade |
Operating Cash Flow | 16.27 | 321.79 | 679.01 | 524.22 | 408.22 | 194.84 | Upgrade |
Operating Cash Flow Growth | -97.44% | -52.61% | 29.53% | 28.42% | 109.52% | 2.09% | Upgrade |
Capital Expenditures | -508.73 | -520.71 | -377.27 | -378.64 | -326.16 | -40.18 | Upgrade |
Sale of Property, Plant & Equipment | 0.14 | 0.11 | 1.65 | 0.45 | 1.35 | 0.09 | Upgrade |
Cash Acquisitions | - | - | - | - | 64.57 | - | Upgrade |
Investment in Securities | 365.16 | 124.3 | 9.25 | -259.36 | -160 | - | Upgrade |
Other Investing Activities | 50.96 | 60.36 | 77.15 | 81.18 | -258.03 | -262.71 | Upgrade |
Investing Cash Flow | -92.47 | -335.94 | -289.21 | -556.38 | -678.28 | -302.81 | Upgrade |
Long-Term Debt Issued | - | 571.81 | 438.32 | 481.79 | 303.16 | 477.06 | Upgrade |
Total Debt Issued | 617.56 | 571.81 | 438.32 | 481.79 | 303.16 | 477.06 | Upgrade |
Long-Term Debt Repaid | - | -415.1 | -316.89 | -263.4 | -833.63 | -235 | Upgrade |
Total Debt Repaid | -458.88 | -415.1 | -316.89 | -263.4 | -833.63 | -235 | Upgrade |
Net Debt Issued (Repaid) | 158.69 | 156.72 | 121.43 | 218.39 | -530.47 | 242.06 | Upgrade |
Issuance of Common Stock | - | 14.22 | 8.3 | 2.51 | 1,597 | 35.2 | Upgrade |
Repurchase of Common Stock | - | - | -24.23 | -21.98 | - | - | Upgrade |
Common Dividends Paid | -375.71 | -264.63 | -66.79 | -49.66 | -12.05 | -178.84 | Upgrade |
Other Financing Activities | -0.06 | -0.06 | -0.47 | -0.8 | 1.76 | -1.76 | Upgrade |
Financing Cash Flow | -217.08 | -93.74 | 38.24 | 148.46 | 1,056 | 96.66 | Upgrade |
Foreign Exchange Rate Adjustments | -0.05 | -0.03 | -0.02 | -1.19 | -0.23 | - | Upgrade |
Net Cash Flow | -293.33 | -107.92 | 428.01 | 115.11 | 785.52 | -11.31 | Upgrade |
Free Cash Flow | -492.47 | -198.92 | 301.74 | 145.58 | 82.06 | 154.66 | Upgrade |
Free Cash Flow Growth | - | - | 107.27% | 77.41% | -46.94% | 3.29% | Upgrade |
Free Cash Flow Margin | -19.66% | -7.49% | 12.96% | 6.05% | 4.16% | 14.73% | Upgrade |
Free Cash Flow Per Share | -0.52 | -0.21 | 0.32 | 0.15 | 0.09 | 0.24 | Upgrade |
Cash Income Tax Paid | 236.54 | 252.75 | 213.87 | 172 | 148.92 | 71.87 | Upgrade |
Levered Free Cash Flow | -668.52 | -316.89 | 186.27 | -7.27 | -289.45 | 36.62 | Upgrade |
Unlevered Free Cash Flow | -660.88 | -310.22 | 192.28 | 0.25 | -282.71 | 48.69 | Upgrade |
Change in Working Capital | -719.35 | -494.83 | -46.5 | -159.95 | -107 | -47.16 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.